Crispr/cas-related methods and compositions for knocking out c5
US-2024415980-A1 · Dec 19, 2024 · US
Modulation of midbody derivatives
US9409978B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9409978-B2 |
| Application number | US-201214342662-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 7, 2012 |
| Priority date | Sep 9, 2011 |
| Publication date | Aug 9, 2016 |
| Grant date | Aug 9, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The number of midbody derivatives in a cell may be modulated by modulating autophagy induced by NBR1. Exemplary methods include modulating the amount or activity of NBR1 in the cell, potentiating or inhibiting binding between NBR1 and Cep55 in the cell, or modulating the amount of Cep55 in the cell. These methods can be used in the treatment of cancers or in methods of reprogramming cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inducing degradation of a midbody derivative in a cancer cell, the method comprising: (a) introducing into the cancer cell a nucleic acid that comprises a sequence encoding a Neighbor of BRCA1 (NBR1 ) polypeptide, a composition comprising an NBR1 polypeptide, or an artificial transcription factor that increases transcription of an NBR1 gene, thereby increasing the amount of NBR1 polypeptide in the cancer cell and inducing degradation of a midbody derivative in the cancer cell. 2. The method of claim 1 , wherein the method comprises introducing into the cancer cell a nucleic acid that comprises a sequence encoding an NBR1 polypeptide. 3. The method of claim 1 , wherein the method comprises introducing into the cancer cell a composition comprising an NBR1 polypeptide or an artificial transcription factor that increases transcription of an NBR1 gene. 4. The method of claim 3 , wherein the composition comprises the NBR1 polypeptide or artificial transcription factor fused with a cell-penetrating peptide, or comprises a liposome. 5. The method of claim 1 , wherein the cancer cell is a cancer stem cell. 6. The method of claim 1 , wherein the cancer cell is in a subject. 7. A method of treating cancer in a subject, the method comprising: (a) introducing into a cancer cell in the subject a nucleic acid that comprises a sequence encoding a Neighbor of BRCA 1 (NBR1 ) polypeptide, a composition comprising an NBR1 polypeptide, or an artificial transcription factor that increases transcription of an NBR1 gene, thereby increasing the amount of NBR1 polypeptide and midbody derivative degradation in cancer cells and treating cancer in the subject. 8. The method of claim 7 , wherein the method comprises introducing into the cancer cell a nucleic acid that comprises a sequence encoding an NBR1 polypeptide. 9. The method of claim 7 , wherein the method comprises introducing into the cancer cell a composition comprising an NBR1 polypeptide or an artificial transcription factor that increases transcription of a NBR1 gene. 10. The method of claim 9 , wherein the composition comprises the NBR1 polypeptide or artificial transcription factor fused with a cell-penetrating peptide, or comprises a liposome. 11. The method of claim 7 , wherein the cancer is a breast cancer. 12. The method of claim 7 , wherein the subject is a human. 13. The method of claim 1 , wherein the nucleic acid is a vector. 14. The method of claim 13 , wherein the vector is a viral vector. 15. The method of claim 1 , wherein the cancer cell is a hepatic cancer cell or an adenocarcinoma cancer cell. 16. The method of claim 7 , wherein the nucleic acid is a vector. 17. The method of claim 16 , wherein the vector is a viral vector. 18. The method of claim 7 , wherein the cancer cell is a cancer stem cell. 19. The method of claim 7 , wherein the cancer is hepatic cancer and the cancer cells are hepatic cancer cells. 20. The method of claim 7 , wherein the cancer is an adenocarcinoma and the cancer cells are adenocarcinoma cancer cells.
Assignees
Inventors
Classifications
from mammals · CPC title
- C07K16/18Primary
against material from animals or humans · CPC title
Antineoplastic agents · CPC title
multispecific · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9409978B2 cover?
- The number of midbody derivatives in a cell may be modulated by modulating autophagy induced by NBR1. Exemplary methods include modulating the amount or activity of NBR1 in the cell, potentiating or inhibiting binding between NBR1 and Cep55 in the cell, or modulating the amount of Cep55 in the cell. These methods can be used in the treatment of cancers or in methods of reprogramming cells.
- Who is the assignee on this patent?
- Doxsey Stephen J, Kuo Tse-Chun, Chen Chun-Ting, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).